4baseCare Raises INR 90 Cr Series B to Expand AI Oncology Platform

This comes two years after the company raised $6 million in Series A funding in 2024, led by Yali Capital with participation from Infosys.

Precision oncology startup 4baseCare has raised INR 90 crore ($9.8 million) in the first close of its Series B funding round, co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backer Yali Capital.

This comes two years after the company raised $6 million in Series A funding in 2024, led by Yali Capital with participation from Infosys.

The new capital will support the expansion of 4baseCare’s hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia. The company will also scale its AI-powered precision oncology platform, OncoTwin, which aids clinical decision-making for cancer treatment.

Founded by Hitesh Goswami, 4baseCare focuses on building population-relevant clinico-genomic datasets to improve cancer diagnosis and treatment outcomes in underrepresented populations. Its platform integrates genomic testing with real-world clinical and outcomes data to deliver actionable insights for oncologists.

OncoTwin was recently selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center, New York, highlighting the platform’s potential for global precision oncology applications.

The startup collaborates closely with hospitals to provide genomics-led cancer diagnostics within clinical settings and is positioning itself for scale in emerging markets.

Investor interest in oncology-focused startups has grown in recent years. In 2025, Everhope Oncology raised $10 million in seed funding, and MOC Cancer Care & Research Centre secured $18 million led by Elevation Capital. Other funded players include ErlySign, OnCare, and OneCell Diagnostics.

Stay tuned for more such updates on Digital Health News